Lu Daopei Medical Group is a private medical group founded in 2012 by Academician Lu Daopei, specializing in the treatment of hematological diseases and tumors, as well as scientific research and education.

The group includes four hospitals:

  • Hebei Yanda Lu Daopei Hospital,

  • Beijing Lu Daopei Hospital,

  • Beijing Lu Daopei Hematology Hospital, and Shanghai Xindaobei Hematology Hospital, with a total of 1,166 beds and 161 sterile wards.

  • Lu Daopei Hospital - a specialized hospital classified as a tertiary medical institution and is recognized by the Beijing medical insurance system.

As a specialized medical institution in the field of hematology, Lu Daopei Medical Group continuously increases its investment in scientific research on hematological diseases and tumors.

In 2024, a total of 58 scientific papers were published, 36 of which received high recognition and evaluation from authoritative experts and scholars both in China and abroad.

The medical team led by Academician Lu consists of more than 300 professionals.

The hospital treats both Chinese patients and patients from other countries. Every year, patients from European countries, as well as Hong Kong, South Korea, Vietnam, Mongolia, and Russia, seek treatment at the hospital.

Since 2019, Lu Daopei Medical Group has become an affiliate of the National Clinical Research Center for Hematological Diseases, established a joint department with the Department of Hematology of Peking University People’s Hospital, and became a teaching base for oncology at Capital Medical University.

Lu Daopei Medical Group treats patients with blood diseases using:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) — a well-established treatment method for various hematological malignancies, immune disorders, and metabolic diseases. Allo-HSCT is often the only curative therapeutic option.

The hematopoietic stem cell transplantation department is one of the most active transplant centers in the world. The number of hematopoietic stem cell transplants performed annually accounts for nearly 10% of all transplants nationwide.

In 2024, 1,470 transplant cases were registered: 1,048 related haploidentical transplants (over 70%); 227 unrelated transplants; 142 related fully matched transplants; 22 unrelated umbilical cord blood transplants; 31 autologous transplants.

Through the study of genetic characteristics of blood diseases and the implementation of effective immunotherapy and targeted therapy technologies, overall cure rates and long-term survival of patients with blood diseases have significantly improved, along with their quality of life.

Lu Daopei Medical Group has been conducting CAR-T clinical trials since July 2015, demonstrating significant efficacy and high safety. As of December 2024, 2,424 patients had participated in CAR-T clinical trials. By March 2025, the number of CAR-T therapies had increased to 2,470 cases, and the outstanding trial results have received recognition and high praise from the international hematology community.